fIPV

BIOLOGICAL2 trials

Sponsors

Centers for Disease Control and Prevention, University of Vermont

Conditions

PolioPoliomyelitis

Phase 1

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

CompletedNCT03922061

University of VermontPolio

Start: 2019-03-19End: 2020-06-04Updated: 2020-08-05

Phase 4

Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study

CompletedNCT03722004

Centers for Disease Control and PreventionPoliomyelitis

Start: 2018-12-18End: 2019-12-19Updated: 2021-02-21

Related Papers

Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.

2023-08-294 citations

Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.

2022-03-3014 citations